|
Search
Collections
Benchmarks
Upload document
ado-trastuzumab emtasine
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers.
Org:
Henry Ford Cancer Institute, Detroit, MI,
Henry Ford Health System,
